drugset / Trial / NCT01741545
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
Timeline
- Start
- 2013-03-31
- Primary completion
- 2015-01-31
- Completion
- 2015-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | Oral |
| Subject | Peginterferon Lambda-1a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Ribavirin | Small molecule | 200 mg | Oral |